Investment Thesis
Recursion Pharmaceuticals is a pre-profitability biotech company with severe operating losses (-$128.5M) relative to minimal revenue ($6.5M), indicating an unsustainable business model in the near term. While the balance sheet is strong with $654.5M in cash and minimal debt providing 8+ years of runway, the -$81.1M annual operating cash burn and negative gross profit model present fundamental concerns. Success depends entirely on unproven clinical pipeline execution.
Strengths
- Strong cash position of $654.5M with minimal debt ($7.2M) providing substantial operational runway
- Excellent liquidity ratios (5.47x current/quick) indicating strong ability to meet short-term obligations
- Positive revenue growth of 26.9% YoY, demonstrating early commercial traction despite tiny absolute base
Risks
- Severe cash burn of $81.1M annually with current revenue of only $6.5M creates deeply unprofitable operations
- Operating margin of -1985.6% indicates company is far from profitability and dependent on pipeline success
- Clinical development and regulatory approval risks inherent to pharmaceutical sector with unproven pipeline as only path to viability
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue growth trajectory and near-term commercialization milestones
- Operating loss trend and progress toward gross margin profitability
Financial Metrics
Revenue
6.5M
Net Income
-117.5M
EPS (Diluted)
$-0.22
Free Cash Flow
-81.4M
Total Assets
1.3B
Cash
654.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,985.6%
Net Margin
-1,815.6%
ROE
-11.5%
ROA
-8.8%
FCF Margin
-1,257.1%
Balance Sheet & Liquidity
Current Ratio
5.47x
Quick Ratio
5.47x
Debt/Equity
0.01x
Debt/Assets
23.5%
Interest Coverage
-6,425.25x
Long-term Debt
7.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T21:01:01.204202 |
Data as of: 2026-03-31 |
Powered by Claude AI